Abingdon Health Ltd is pleased to announce the appointment of Biomedical Diagnostics (“BMD”) as an exclusive distributor for Belgium, The Netherlands and Luxembourg (“Benelux”) for the Seralite® – FLC rapid diagnostic test.
Seralite® – FLC is a rapid diagnostic device for the quantitative measurement of kappa (K) and lambda (λ) immunoglobulin free light chains (FLCs) in serum as an aid to the diagnosis and management of multiple myeloma. The assay provides an accurate picture of disease status in 10 minutes. The simple to use, portable, rapid test allows the monitoring of patients in “real time” supporting faster decision making. By obtaining results rapidly, clinicians are able to better understand disease status and can make informed treatment decisions quickly and efficiently.
Biomedical Diagnostics (BMD) is a privately owned company which was founded in December 1986. Based in Antwerp, BMD is a distributor of reagents, instruments and technical support to clinics and laboratories in Belgium, The Netherlands and Luxembourg.
Commenting on the agreement, Chris Yates, said:
“We are delighted to announce BMD as our distributor. BMD are a well-established company with an experienced field based sales force in the Benelux region and we are confident they will be an excellent partner to support the roll-out of the Seralite® – FLC device across the region.”
Full press release: Seralite® – FLC distributor appointed for Benelux